Home Upload Photo Upload Videos Write a Blog Analytics Messaging Streaming Create Adverts Creators Program
Bebuzee Afghanistan Bebuzee Albania Bebuzee Algeria Bebuzee Andorra Bebuzee Angola Bebuzee Antigua and Barbuda Bebuzee Argentina Bebuzee Armenia Bebuzee Australia Bebuzee Austria Bebuzee Azerbaijan Bebuzee Bahamas Bebuzee Bahrain Bebuzee Bangladesh Bebuzee Barbados Bebuzee Belarus Bebuzee Belgium Bebuzee Belize Bebuzee Benin Bebuzee Bhutan Bebuzee Bolivia Bebuzee Bosnia and Herzegovina Bebuzee Botswana Bebuzee Brazil Bebuzee Brunei Bebuzee Bulgaria Bebuzee Burkina Faso Bebuzee Burundi Bebuzee Cabo Verde Bebuzee Cambodia Bebuzee Cameroon Bebuzee Canada Bebuzee Central African Republic Bebuzee Chad Bebuzee Chile Bebuzee China Bebuzee Colombia Bebuzee Comoros Bebuzee Costa Rica Bebuzee Côte d'Ivoire Bebuzee Croatia Bebuzee Cuba Bebuzee Cyprus Bebuzee Czech Republic Bebuzee Democratic Republic of the Congo Bebuzee Denmark Bebuzee Djibouti Bebuzee Dominica Bebuzee Dominican Republic Bebuzee Ecuador Bebuzee Egypt Bebuzee El Salvador Bebuzee Equatorial Guinea Bebuzee Eritrea Bebuzee Estonia Bebuzee Eswatini Bebuzee Ethiopia Bebuzee Fiji Bebuzee Finland Bebuzee France Bebuzee Gabon Bebuzee Gambia Bebuzee Georgia Bebuzee Germany Bebuzee Ghana Bebuzee Greece Bebuzee Grenada Bebuzee Guatemala Bebuzee Guinea Bebuzee Guinea-Bissau Bebuzee Guyana Bebuzee Haiti Bebuzee Honduras Bebuzee Hong Kong Bebuzee Hungary Bebuzee Iceland Bebuzee India Bebuzee Indonesia Bebuzee Iran Bebuzee Iraq Bebuzee Ireland Bebuzee Israel Bebuzee Italy Bebuzee Jamaica Bebuzee Japan Bebuzee Jordan Bebuzee Kazakhstan Bebuzee Kenya Bebuzee Kiribati Bebuzee Kuwait Bebuzee Kyrgyzstan Bebuzee Laos Bebuzee Latvia Bebuzee Lebanon Bebuzee Lesotho Bebuzee Liberia Bebuzee Libya Bebuzee Liechtenstein Bebuzee Lithuania Bebuzee Luxembourg Bebuzee Madagascar Bebuzee Malawi Bebuzee Malaysia Bebuzee Maldives Bebuzee Mali Bebuzee Malta Bebuzee Marshall Islands Bebuzee Mauritania Bebuzee Mauritius Bebuzee Mexico Bebuzee Micronesia Bebuzee Moldova Bebuzee Monaco Bebuzee Mongolia Bebuzee Montenegro Bebuzee Morocco Bebuzee Mozambique Bebuzee Myanmar Bebuzee Namibia Bebuzee Nauru Bebuzee Nepal Bebuzee Netherlands Bebuzee New Zealand Bebuzee Nicaragua Bebuzee Niger Bebuzee Nigeria Bebuzee North Korea Bebuzee North Macedonia Bebuzee Norway Bebuzee Oman Bebuzee Pakistan Bebuzee Palau Bebuzee Panama Bebuzee Papua New Guinea Bebuzee Paraguay Bebuzee Peru Bebuzee Philippines Bebuzee Poland Bebuzee Portugal Bebuzee Qatar Bebuzee Republic of the Congo Bebuzee Romania Bebuzee Russia Bebuzee Rwanda Bebuzee Saint Kitts and Nevis Bebuzee Saint Lucia Bebuzee Saint Vincent and the Grenadines Bebuzee Samoa Bebuzee San Marino Bebuzee São Tomé and Príncipe Bebuzee Saudi Arabia Bebuzee Senegal Bebuzee Serbia Bebuzee Seychelles Bebuzee Sierra Leone Bebuzee Singapore Bebuzee Slovakia Bebuzee Slovenia Bebuzee Solomon Islands Bebuzee Somalia Bebuzee South Africa Bebuzee South Korea Bebuzee South Sudan Bebuzee Spain Bebuzee Sri Lanka Bebuzee Sudan Bebuzee Suriname Bebuzee Sweden Bebuzee Switzerland Bebuzee Syria Bebuzee Taiwan Bebuzee Tajikistan Bebuzee Tanzania Bebuzee Thailand Bebuzee Timor-Leste Bebuzee Togo Bebuzee Tonga Bebuzee Trinidad and Tobago Bebuzee Tunisia Bebuzee Turkey Bebuzee Turkmenistan Bebuzee Tuvalu Bebuzee Uganda Bebuzee Ukraine Bebuzee United Arab Emirates Bebuzee United Kingdom Bebuzee Uruguay Bebuzee Uzbekistan Bebuzee Vanuatu Bebuzee Venezuela Bebuzee Vietnam Bebuzee World Wide Bebuzee Yemen Bebuzee Zambia Bebuzee Zimbabwe
Blog Image

New blood test can help doctors diagnose tuberculosis and monitor treatment

Researchers have developed a new highly sensitive blood test for tuberculosis (TB) that screens for DNA fragments of the Mycobacterium tuberculosis bacteria that causes the deadly disease.

Researchers at Tulane University School of Medicine have developed a new highly sensitive blood test for tuberculosis (TB) that screens for DNA fragments of the Mycobacterium tuberculosis bacteria that causes the deadly disease.

The test could give doctors a new tool to both quickly identify TB and then gauge whether drug treatments are effective by monitoring levels of DNA from the pathogen circulating through the bloodstream, according to a new study published in the journal The Lancet Microbe.

Tuberculosis is now the second most deadly infectious disease in the world, behind only COVID-19. In 2020, an estimated 10 million people contracted TB and 1.5 million people died from it, according to the World Health Organization.

Most TB tests rely on screening sputum, a thick type of mucus from the lungs. But collecting sputum from patients suspected of having TB can be difficult, especially for children. TB can also be harder to diagnose in immunocompromised HIV patients and others where the infection migrates outside of the lungs into other areas of the body. In these extrapulmonary cases, patients can have little bacteria in the sputum, which leads to false negatives using current testing methods, said lead study author Tony Hu, PhD, Weatherhead Presidential Chair in Biotechnology Innovation at Tulane University.

"This assay may be a game-changer for TB diagnoses that not only provides accurate diagnosis results but also has the potential to predict disease progression and monitor treatment," Hu said. "This will help doctors rapidly intervene in treatment and reduce the risk of death, especially for children living with HIV."

The study evaluated a CRISPR-based assay that screened for cell-free DNA from live Mycobacterium tuberculosis bacilli. The screening target is released into the bloodstream and cleared quite rapidly, providing a real-time snapshot of active infection.

Researchers tested preserved blood samples from 73 adults and children with presumptive TB and their asymptomatic household contacts in Eswatini, Africa.

The test identified adult TB with 96.4% sensitivity and 94.1% specificity and pediatric TB with 83.3% sensitivity and 95.5% specificity. (Sensitivity refers to how well a test can diagnose a positive case, while specificity is a measure of a test's accurately determining a negative case.)

Researchers also tested 153 blood samples from a cohort of hospitalized children in Kenya. These were HIV-positive patients who were at high risk for TB and presented with at least one symptom of the disease. The new test picked up all 13 confirmed TB cases and almost 85% of unconfirmed cases, which were cases that were diagnosed due to clinical symptoms and not existing gold standard testing methods. Read More…

Previous Post

Secrets of tree hyraxes in Kenya uncovered with new research techniques

Next Post

Prof Faith Osier appointed Co-Director of Imperial's Institute of Infection

Comments